GLP-1 agonists are being used in combination with basal insulin (Dungan & DeSantis, 2016), although this is not an FDA-approved indication (see rxlist.com) they should not be used as a substitute for basal insulin, as this has been found to result in a decline in glycemic control)(Dungan & DeSantis, 2016) Clinical trials indicate it can reduce HbA1c by ~0.8% Undergoes renal clearance, with dosage reduction needed if creatinine clearance falls to 1.5
Some patients achieve excellent results with semaglutide alone, while others require tirzepatide's dual action to reach their goals
Higher doses are generally linked to greater weight loss but only when the increase is done safely and under medical supervision
Both are important in the weight loss conversation, but they are different
Sus propiedades ergognicas, le confieren el ser de utilidad en el manejo de estrs fisiolgico o estados carenciales
Previous studies looking at GLP-1 drugs and the brain have suggested that the drugs may slow the loss of volume in the parts of the brain required for planning, memory, emotion and sensory integration
